Patent ID: 7192595

Claim:
A human synthetic peptide-based influenza vaccine, comprising at least four epitopes of influenza virus, said influenza virus epitopes being reactive with human cells, wherein said epitopes comprise: (a) at least one B-cell hemagglutinin (HA) epitope consisting of the influenza virus hemagglutinin epitope 91–108 (HA 91–108) of SEQ ID NO:1; (b) at least one T-helper epitope selected from the group consisting of the influenza virus hemagglutinin epitope 307–319 (HA 307–319) of SEQ ID NO:2, influenza virus hemagglutinin epitope 306–324 (HA 306–324) of SEQ ID NO:3 and the nucleoprotein epitope 206–229 (NP 206–229) of SEQ ID NO:11, each epitope being capable of binding to many HLA molecules; and (c) at least two cytotoxic lymphocyte (CTL) epitopes selected from the group consisting of NP265–273 of SEQ ID NO:12, NP305–313 of SEQ ID NO:13 and influenza virus matrix protein epitope M2–12 of SEQ ID NO:10.